Catalyst Crew Technologies Corp. (OTC: CCTC) announced today that it has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (SEC) disclosing a material change in its business direction and corporate strategy. The Company is transitioning from its prior business focus to pursue operations as a development-stage artificial intelligence-enabled healthcare technology company, with an initial focus on Latin America and other emerging markets. A copy of the Company’s Form 8-K is available for review on the SEC’s EDGAR database at https://www.sec.gov/Archives/edgar/data/1840439/000119312526068375/d95198d8k.htm.
The Company’s anticipated areas of focus include development of AI-driven healthcare software platforms, telehealth and remote patient monitoring technologies, clinical data analytics and interoperability systems, and healthcare workflow and administrative automation solutions. Additionally, the Company plans to pursue strategic acquisitions and partnerships within the healthcare technology sector. However, it remains in the development stage of this strategic transition and is actively implementing its new plan of operations. There can be no assurance that the Company will successfully implement its new business plan, secure financing, complete acquisitions, enter into definitive agreements, or generate revenues.
In connection with its revised strategic direction, the Company intends to change its corporate name to LataMed AI Corp. The proposed name change is expected to be effected through the filing of Articles of Amendment with the State of Nevada and is subject to required corporate approvals. Furthermore, the Company intends to submit a Company Related Action Notification Form and supporting documentation to the Financial Industry Regulatory Authority (FINRA), pursuant to Rule 6490 and related FINRA procedures, requesting review and processing of both the corporate name change and a corresponding ticker symbol change. The filing of Articles of Amendment and submission to FINRA are procedural steps, and neither the corporate name change nor ticker symbol change will become effective until FINRA completes its review and announces the effective date. There can be no assurance regarding the timing of FINRA’s review or that FINRA will approve the requested corporate action. The Company will issue a subsequent press release upon confirmation of the effective date.
The Company intends to continue meeting its reporting obligations under the Securities Exchange Act of 1934 and will provide updated disclosures through filings with the SEC and through OTC Markets Group. It is also developing a new corporate website to reflect its updated business direction and branding.
This strategic pivot to AI-enabled healthcare technology positions the Company to address the growing demand for modernized healthcare delivery systems in emerging markets, particularly in Latin America. By focusing on telehealth, remote patient monitoring, and data analytics, the Company aims to improve access, efficiency, and care coordination. However, as a development-stage enterprise, it has not yet generated revenues from its new business direction. Investors are urged to carefully review all risk factors and disclosures contained in the Company’s SEC filings before making any investment decision.
